Greehey CCRI News & Events Archive
Pediatric Blood & Cancer: In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC) (Kurmasheva, Houghton)
August 30, 2021Raushan T. Kurmasheva, Stephen W. Erickson, Ruolan Han, Beverly A. Teicher, Malcolm A. Smith, Michael Roth, Richard Gorlick, Peter J. Houghton Abstract SP-2577(Seclidemstat), an inhibitor of lysine-specific demthylase KDM1A (LSD1) that is overexpressed …
Drs Houghton and Kurmasheva to Receive 5-year, $2.9M NCI Pediatric In Vivo Testing Program (PIVOT) U01 Grant Renewal
August 10, 2021NCI Pediatric In Vivo Testing Program (U01), renewal for the previous PPTC (Pediatric Preclinical Testing Consortium). Grant period: July 2021-June 2026. Total dollar amount: $2,900,000 over 5 years. Abstract Cancer in children is rare with …
Drs. Tomlinson and Kurmasheva to be Profiled in San Antonio Woman Magazine Article
July 23, 2021Journal of Clinical Medicine: Recent Developments in Nanomedicine for Pediatric Cancer (Kurmasheva)
April 30, 2021by Shicheng Yang 1, Mia Wallach 2 , Apurva Krishna 3, Raushan Kurmasheva 4,5,*,† and Srinivas Sridhar 1,3,6,*,† Abstract Cancer is the second biggest cause of death in children in the US. With the development of chemotherapy, there has been a substan …
A review article by Raushan Kurmasheva (senior author) gives an overview on recent developments in nanomedicine for pediatric cancer
April 30, 2021Recent Developments in Nanomedicine for Pediatric Cancer by Shicheng Yang 1, Mia Wallach 2OrcID, Apurva Krishna 3, Raushan Kurmasheva 4,5,*,†OrcID and Srinivas Sridhar 1,3,6,*,† Abstract Cancer is the second biggest cause of death in children in the US …
The Journal of Clinical Medicine Special Issue: The Current Treatment of Childhood Cancer”, for which Dr. Raushan Kurmasheva is Guest Editor
April 20, 2021Special Issue Information Dear Colleagues, In the last four decades, the 5-year survival rate of children with cancer has increased from 58% to 83%, with the standard of care for these children relying on surgery, radiation therapy, and systemic therap …
EurekAlert: Researchers (Houghton & Kurmasheva part of team who) identify surface protein as a new osteosarcoma therapeutic target for antibody-drug conjugates
April 13, 2021Novel approach paves the way for a vast expansion in the number of drugs targeting osteosarcoma Abstract #LB008 HOUSTON — A preclinical study led by researchers at The University of Texas MD Anderson Cancer Center shows an antibody-drug conjugate (ADC …
APPLICATIONS NOW BEING ACCEPTED: Greehey CCRI Donald G McEwen, Memorial Summer 2021 Undergraduate Research Program
April 6, 2021Applications are now being accepted for the Greehey CCRI Undergraduate Summer Internship Program. The purpose of the Greehey CCRI Undergraduate Summer Internship Program is to allow talented undergraduate students interested in a career in academic r …
MDPI: Samson Ghilu, Raushan Kurmasheva, and Peter Houghton publish a perspective on developing new agents for treatment of childhood cancer, and its challenges and opportunities for preclinical testing
April 4, 2021Abstract Developing new therapeutics for the treatment of childhood cancer has challenges not usually associated with adult malignancies. Firstly, childhood cancer is rare, with approximately 12,500 new diagnoses annually in the U.S. in children 18 yea …
Cancer Research: A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models (Houghton, Kurmasheva)
February 19, 2021Shaun D. Fontaine, Gary W. Ashley, Peter J. Houghton, Raushan T. Kurmasheva, Morgan Diolaiti, Alan Ashworth, Cody J. Peer, Ryan Nguyen, William D. Figg Sr., Denis R. Beckford-Vera, and Daniel V. Santi Abstract PARP inhibitors are approved for the treat …
-
Page 1 out of 4
- Next